Conditional c-MYC activation in catecholaminergic cells drives distinct neuroendocrine tumors: neuroblastoma vs somatostatinoma

Tingting Wang,Lingling Liu,Jie Fang,Hongjian Jin,Sivaraman Natarajan,Heather Sheppard,Meifen Lu,Gregory Turner,Thomas Confer,Melissa Johnson,Jeffrey Steinberg,Larry Ha,Nour Yadak,Richa Jain,David J. Picketts,Xiaotu Ma,Andrew Murphy,Andrew M. Davidoff,Evan S. Glazer,John Easton,Xiang Chen,Ruoning Wang,Jun Yang

DOI: https://doi.org/10.1101/2024.03.12.584622

2024-03-14

Abstract:The MYC proto-oncogenes (c-MYC, , ) are among the most deregulated oncogenic drivers in human malignancies including high-risk neuroblastoma, 50% of which are -amplified. Genetically engineered mouse models (GEMMs) based on the transgene have greatly expanded the understanding of neuroblastoma biology and are powerful tools for testing new therapies. However, a lack of c-MYC–driven GEMMs has hampered the ability to better understand mechanisms of neuroblastoma oncogenesis and therapy development given that c-MYC is also an important driver of many high-risk neuroblastomas. In this study, we report two transgenic murine neuroendocrine models driven by conditional c-MYC induction in tyrosine hydroxylase (Th) and dopamine β-hydroxylase (Dbh)-expressing cells. c-MYC induction in Th-expressing cells leads to a preponderance of Pdx1 somatostatinomas, a type of pancreatic neuroendocrine tumor (PNET), resembling human somatostatinoma with highly expressed gene signatures of δ cells and potassium channels. In contrast, c-MYC induction in Dbh-expressing cells leads to onset of neuroblastomas, showing a better transforming capacity than MYCN in a comparable C57BL/6 genetic background. The c-MYC murine neuroblastoma tumors recapitulate the pathologic and genetic features of human neuroblastoma, express GD2, and respond to anti-GD2 immunotherapy. This model also responds to DFMO, an FDA-approved inhibitor targeting ODC1, which is a known MYC transcriptional target. Thus, establishing c-MYC–overexpressing GEMMs resulted in different but related tumor types depending on the targeted cell and provide useful tools for testing immunotherapies and targeted therapies for these diseases.

Cancer Biology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to establish new mouse genetic engineering models (GEMMs) by conditionally activating the expression of the c - MYC gene in specific cell types, in order to better understand the occurrence mechanisms of neuroendocrine tumors, especially the formation mechanisms of neuroblastoma and somatostatinoma. Specifically:

1. **Construction of the neuroblastoma model**: By conditionally activating c - MYC in dopamine β - hydroxylase (Dbh) - positive cells, the research team hopes to develop a mouse model that can more realistically simulate high - risk human neuroblastoma. This model can not only be used to deeply explore the pathogenesis of neuroblastoma, but also serve as an effective tool for testing new treatment methods.

2. **Construction of the insulinoma model**: By conditionally activating c - MYC in tyrosine hydroxylase (Th) - positive cells, the research team found that tumors similar to human insulinoma can be induced. These tumors mainly originate from pancreatic δ cells and exhibit molecular characteristics and pathological features similar to those of human insulinoma.

3. **Effects of c - MYC activation in different cell types**: By comparing the types of tumors formed after activating c - MYC in different cell types, the research team aims to reveal how the same oncogene leads to different tumor entities when activated under different temporal and spatial conditions. This finding helps to understand the complexity and diversity of tumorigenesis and provides a theoretical basis for future personalized treatment.

In general, this study not only fills the gap in the field of c - MYC - driven neuroblastoma genetic engineering models, but also provides new tools and perspectives for the research of neuroendocrine tumors.